news.google.com· FierceBiotech·· 17 hours agoPickScore71
Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde - Fierce Biotech
In brief
Gilead will pay $1.3 billion upfront for rights to PepStar's oral IL-23 inhibitor, aiming to challenge Johnson & Johnson's Icotyde.
Why it matters
The brief discloses the upfront amount and target, letting readers gauge the asset's valuation.
Source: news.google.com · news.google.com